pharmaceuticals

pharmaceuticals Articles

Theravance Biopharma has announced that the FDA approved its supplemental New Drug Application for Vibativ (telavancin) to expand the product's label.
Horizon Pharma reported better-than-expected first-quarter financial results before the markets opened on Monday.
When Endo International reported its first-quarter financial results on Thursday, earnings vastly underwhelmed, and analysts definitely had something to say about it.
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
Endo International reported mixed first-quarter financial results after the markets closed on Thursday.
Drug giant Merck reported mixed first-quarter 2016 results before markets opened Thursday morning.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates for generic...
Credit Suisse's new Neutral rating on Teva Pharmaceutical Industries actually comes with significant upside.
Viamet Pharmaceuticals intends to price more than 5 million shares within the range of $14 to $16 per share for an initial public offering valued up to almost $105 million.
Infectious diseases always have been a hot topic in biotech, but over the past half decade more capital has been drawn into the space.
Pfizer is scheduled to report its first-quarter financial results before the markets open on Tuesday.
One portfolio manager on CNBC noted that Vertex could end up being an acquisition target ahead, without mentioning any specifics.
AbbVie reported its first-quarter financial results and guidance before the markets opened on Thursday.
The April 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks short interest was mixed.
If Moody's is correct, pharmaceutical earnings will keep growing for at least the next year and a half.